Autres langues OKYO Pharma Limited

Actions

EMMLD

GG00BMFG5F62

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 17/06/2024			Varia. 5j.	Varia. 1 janv.
1,3 ^USD	-0,62%		-4,33%	-26,55%

22/03	OKYO PHARSADR : HC Wainwright maintient sa recommandation à l'achat	ZM
22/03	OKYO Pharma annonce que le OK-101 a atteint avec succès une signification statistique pour de multiples signes et symptômes de la maladie des yeux secs, y compris le soulagement de la douleur oculaire, dans le cadre de son premier essai de phase 2 chez l'humain.	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

OKYO Pharma Announces Participation in May 2024 Investor Conferences	08/05
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	30/04
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	09/04
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	02/04
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	20/03
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	20/03
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09/02
Sector Update: Health Care	09/02
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	09/02
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	31/01
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	31/01
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	08/01
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease	08/01
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	05/01
OKYO PHARSADR : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	18/12
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	04/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues OKYO Pharma Limited

Actions

EMMLD

GG00BMFG5F62

Autres langues

Filtres